Alkem Laboratories Ltd. (IN:ALKEM)
:ALKEM
Top Page
Alkem Laboratories Ltd.
(ALKEM)
Select Model
Select Model
Rating:72Outperform
Price Target:
₹5,717.00
▲(2.86% Upside)
Action:UpgradedDate:08/13/25
Alkem Laboratories demonstrates strong financial performance with robust revenue growth and profitability, which is the most significant factor in its score. Technical analysis supports a positive trend, although valuation metrics suggest the stock may be overvalued. The absence of earnings call data and corporate events did not impact the score.
Positive Factors
Revenue Growth
The 11% revenue growth in Q1 FY26 demonstrates Alkem's strong market position and effective expansion strategies in both domestic and international markets.
Negative Factors
Declining Cash Flow
The decline in free cash flow, despite remaining positive, could limit Alkem's capacity to fund new projects or manage unexpected expenses, impacting long-term growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The 11% revenue growth in Q1 FY26 demonstrates Alkem's strong market position and effective expansion strategies in both domestic and international markets.
Read all positive factors
Alkem Laboratories Ltd. (ALKEM) vs. iShares MSCI India ETF (INDA)
Market Cap
₹650.45B
Dividend Yield0.8%
Average Volume (3M)9.84K
Price to Earnings (P/E)26.0
Beta (1Y)0.58
Revenue Growth9.32%
EPS Growth11.25%
CountryIN
Employees17,432
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)53.19
Shares Outstanding119,565,000
10 Day Avg. Volume12,022
30 Day Avg. Volume9,843
Financial Highlights & Ratios
PEG Ratio1.30
Price to Book (P/B)4.82
Price to Sales (P/S)4.52
P/FCF Ratio46.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹6,550.00Price Target Upside17.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)194.03
Revenue Forecast (FY)₹162.95B
Alkem Laboratories Ltd. Business Overview & Revenue Model
Company Description
Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceu...
How the Company Makes Money
Alkem Laboratories generates revenue through multiple key streams, primarily from the sale of pharmaceutical formulations in domestic and international markets. The company achieves significant earnings from its extensive generic product line, whi...
Alkem Laboratories Ltd. Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
75
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 138.90B | 128.05B | 124.39B | 114.40B | 105.12B | 87.28B |
| Gross Profit | 81.06B | 79.47B | 74.07B | 64.58B | 62.29B | 51.42B |
| EBITDA | 31.57B | 29.71B | 24.18B | 17.09B | 21.89B | 21.66B |
| Net Income | 23.61B | 21.65B | 17.96B | 9.84B | 16.46B | 15.85B |
Balance Sheet | ||||||
| Total Assets | 202.87B | 176.91B | 155.75B | 137.57B | 140.69B | 115.19B |
| Cash, Cash Equivalents and Short-Term Investments | 51.52B | 37.78B | 42.70B | 11.43B | 13.13B | 17.54B |
| Total Debt | 23.56B | 13.81B | 14.18B | 13.97B | 26.68B | 17.92B |
| Total Liabilities | 64.77B | 52.57B | 48.60B | 43.22B | 52.22B | 39.61B |
| Stockholders Equity | 133.46B | 119.85B | 103.12B | 90.45B | 86.38B | 73.77B |
Cash Flow | ||||||
| Free Cash Flow | 4.40B | 12.37B | 16.89B | 14.50B | 7.72B | 10.70B |
| Operating Cash Flow | 8.37B | 19.13B | 19.48B | 16.82B | 11.11B | 12.65B |
| Investing Cash Flow | -15.68B | -12.99B | -10.09B | 1.13B | -14.35B | -9.99B |
| Financing Cash Flow | 4.63B | -8.11B | -11.45B | -17.61B | 3.80B | -2.72B |
Alkem Laboratories Ltd. Technical Analysis
Positive
5558.15
Price Trends
5472.80
Negative
5545.79
Negative
5376.05
Positive
Market Momentum
-46.82
Negative
53.86
Neutral
71.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALKEM, the sentiment is Positive. The current price of 5558.15 is above the 20-day moving average (MA) of 5315.58, above the 50-day MA of 5472.80, and above the 200-day MA of 5376.05, indicating a neutral trend. The MACD of -46.82 indicates Negative momentum. The RSI at 53.86 is Neutral, neither overbought nor oversold. The STOCH value of 71.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ALKEM.
Alkem Laboratories Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹784.08B | 18.87 | ― | 0.33% | 7.33% | -3.79% | |
72 Outperform | ₹650.45B | 25.97 | ― | 0.80% | 9.32% | 11.25% | |
69 Neutral | ₹129.88B | 21.31 | ― | 0.31% | 11.41% | 19.22% | |
67 Neutral | ₹547.60B | 41.01 | ― | 1.68% | 10.69% | 17.46% | |
63 Neutral | ₹405.43B | 35.44 | ― | 2.16% | 4.17% | 41.51% | |
53 Neutral | ₹610.37B | 35.61 | ― | 0.24% | 30.27% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:ALKEM
Alkem Laboratories Ltd.
5,440.10
606.74
12.55%
IN:ABBOTINDIA
Abbott India Limited
25,770.05
-4,804.11
-15.71%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,350.00
219.10
19.37%
IN:CAPLIPOINT
Caplin Point Laboratories Limited
1,708.70
-213.34
-11.10%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,393.25
-446.44
-15.72%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,162.90
790.87
57.64%
Alkem Laboratories Ltd. Corporate Events
Alkem Laboratories Closes Trading Window Ahead of December-Quarter Results
Dec 23, 2025
Alkem Laboratories Ltd. has announced that its trading window for dealing in the company’s securities will be closed from 30 December 2025 until 48 hours after the financial results for the quarter and nine months ended 31 December 2025 are ...
Alkem Laboratories Schedules Analyst and Investor Meetings for December 2025
Dec 8, 2025
Alkem Laboratories Ltd. has announced a schedule for upcoming meetings with analysts and institutional investors, set to occur in December 2025. These meetings, which will be held in person in Mumbai, are part of the company’s efforts to eng...
Alkem Laboratories Announces Senior Management Change
Dec 8, 2025
Alkem Laboratories Ltd. announced the resignation of Mr. Rakesh Tripathi from his Senior Management position, effective December 8, 2025, due to personal commitments. The company expressed appreciation for Mr. Tripathi’s contributions during...
Alkem Laboratories Schedules Investor Meeting for Strategic Insights
Nov 25, 2025
Alkem Laboratories Ltd. has announced an upcoming one-on-one meeting with analysts and institutional investors as part of the Citi India Pharma Healthcare Tour 2025, scheduled for November 28, 2025, in Mumbai. This engagement is expected to provi...
Alkem Laboratories’ Sikkim Facility Passes Armenian GMP Inspection
Nov 22, 2025
Alkem Laboratories Ltd. announced that a recent Good Manufacturing Practice (GMP) inspection by the Ministry of Health, Armenia, at its Sikkim, India facility concluded without any critical or major observations. This successful inspection undersc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.